Nicorette 2 mg and 4 mg cleared for OTC use by FDA advisory committee.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM NICORETTE Rx-TO-OTC SWITCH RECOMMENDED FOR APPROVAL at a joint meeting of FDA's Nonprescription Drugs and Drug Abuse Advisory Committees on Sept. 28. The joint committee unanimously agreed that the product is "safe and effective for self-medication when used as directed" at both 2 and 4 mg doses.